Why Is Retail Going Gaga Over INTS Stocks Today?
Synopsis
The firm announced positive data from a study of INT230-6 in the treatment of metastatic and refractory cancers, with 15 of 64 patients in the trial surviving for more than 21 months.
Shares of Intensity Therapeutics, Inc. (INTS) jumped 188% on Thursday morning after the company announced the publication of positive data from a study of INT230-6 in the treatment of metastatic and refractory cancers.
In heavily pretreated patients with advanced disease having over 20 different types of cancer who had progressed following multiple prior lines of therapy, intratumoral INT230-6 achieved a disease control rate of 75% and a median overall survival of 11.9 months in the trial, the company said.
In patients with metastatic sarcoma receiving only INT230-6, the median overall survival was 21.3 months, the company noted. In a clinical trial, measuring the median overall survival is one way to assess the effectiveness of a new treatment.
Furthermore, 15 of 64 patients in the trial survived for more than 21 months, the company noted.
Get updates to this developing story <directly on Stocktwits.<
Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business.